Obesity drug is trialled
VERNALIS has started a Phase I trial of a potential treatment for obesity, type II diabetes and related disorders.
The randomised, placebo-controlled study in overweight and mildly obese volunteers will be conducted in two parts - a single ascending dose followed by a multiple ascending dose and is expected to complete in mid-2007.
The primary objectives of the Phase I programme are to evaluate the safety, tolerability and pharmacokinetics of single and multiple doses of the treatment.
Simon Sturge, CEO of Grant Park-based Vernalis, said: "There are only two drugs approved in the United States for long-term treatment of obesity, both of which are limited by side effects.
"Prevalence of obesity in the US and Europe has reached epidemic levels and there is a clear opportunity for an effective and well-tolerated anti-obesity drug."
Diet pill trial